Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Gastroenterology
Erschienen in: Current Treatment Options in Gastroenterology 4/2020

11.11.2020 | Hot Topics

Who Needs Gastroprotection in 2020?

verfasst von: Takeshi Kanno, Paul Moayyedi, BSc MB ChB PhD MPH FRCP FRCPC AGAF, FACG, CAGF

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Peptic ulcer disease (PUD) is a recognized complication of non-steroidal anti-inflammatory drugs (NSAIDs). Stress ulcers are a concern for intensive care unit (ICU) patients; PUD is also an issue for patients taking anticoagulation. Helicobacter pylori test and treat is an option for patients starting NSAID therapy, and proton pump inhibitors (PPIs) may reduce PUD in NSAID patients and other high-risk groups.

Recent findings

There are a large number of trials that demonstrate that Helicobacter pylori eradication reduces PUD in NSAID patients. PPI is also effective at reducing PUD in this group and is also effective in ICU patients and those on anticoagulants. The effect is too modest for PPI to be recommended in everyone, and more research is needed as to which groups would benefit the most. Increasing age, past history of PUD, and comorbidity are the most important risk factors.

Summary

H. pylori test and treat should be offered to older patients starting NSAIDS, while PPIs should be prescribed to patients that are at high risk of developing PUD and at risk of dying from PUD complications.
Literatur
1.
Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012;107:1190–5.PubMed
2.
van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98:1494–9.PubMed
3.
Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg. 2010;251:51–8.PubMed
4.
Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta- analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ. 2005;330:568–70.PubMedPubMedCentral
5.
6.
Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009;29:938–46.PubMed
7.
Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84:102–13.PubMed
8.
Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156:254–72.PubMed
9.
Fassio V, Aspinall SL, Zhao X, et al. Trends in opioid and nonsteroidal anti-inflammatory use and adverse events. Am J Manag Care. 2018;24:e61–72.PubMed
10.
11.
12.
Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390:613–24.PubMed
13.
Åhsberg K, Höglund P, Staël von Holstein C. Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther. 2010;32:801–10.PubMed
14.
Vaduganathan M, Bhatt DL. Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem. Clin Gastroenterol Hepatol. 2017;15:691–3.PubMed
15.
Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: guideline recommendations from the international consensus group. Ann Intern Med. 2019;171:805–22.PubMedPubMedCentral
16.
Sung JJ, Chiu PW, Chan FKL, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2018;67:1757–68.PubMed
17.
18.
Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29:481–96.PubMed
19.
Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of Gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134:937–44.PubMed
20.
Thorsen K, Søreide JA, Kvaløy JT, Glomsaker T, Søreide K. Epidemiology of perforated peptic ulcer: age- and gender-adjusted analysis of incidence and mortality. World J Gastroenterol. 2013;19:347–54.PubMedPubMedCentral
21.
García Rodríguez LA, Ruigómez A, Hasselgren G, Wallander MA, Johansson S. Comparison of mortality from peptic ulcer bleed between patients with or without peptic ulcer antecedents. Epidemiology. 1998;9:452–6.PubMed
22.
23.
Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105–18.PubMedPubMedCentral
24.
Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti- inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–8.PubMedPubMedCentral
25.
Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, et al. Individual NSAIDs and upper gastrointestinal complications. Drug Saf. 2012;35:11127–46.
26.
Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9:762–8.PubMed
27.
Tramèr MR, Moore AR, Reynolds JM, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;85:169–82.PubMed
28.
Yusuf S, Zhao F, Metha SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.PubMed
29.
Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A. 2001;98:6470–5.PubMedPubMedCentral
30.
Grove EL, Würtz M, Schwarz P, Jørgensen NR, Vestergaard P. Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. J Gen Intern Med. 2013;28:216–22.PubMed
31.
Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long term oral anticoagulant therapy. Arch Intern Med. 1988;148:1733–6.PubMed
32.
33.
34.
Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ. 2001;322:321–6.PubMedPubMedCentral
35.
Ruff CT, Guigliano RP, Braunwald E, Hoffman EB, Deenadayalu N, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.PubMed
36.
37.
Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2016;152:1014–22.PubMed
38.
Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505.PubMedPubMedCentral
39.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30.PubMed
40.
Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.PubMed
41.
Ramamoorthy S, Cidlowski JA. Corticosteroid-mechanisms of action in health and disease. Rheum Dis Clin N Am. 2017;42:15–31.
42.
Martinek J, Hlavova K, Zavada F, et al. “A surviving myth”—corticosteroids are still considered ulcerogenic by a majority of physicians. Scand J Gastroenterol. 2010;45:1156–61.PubMed
43.
44.
Hemels ME, Koren G, Einarson TR. Increased use of antidepressants in Canada: 1981–2000. Ann Pharmacother. 2002;36:1375–9.PubMed
45.
Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterology. 2019;114:21–39.
46.
47.
Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006;119:113–6.PubMed
48.
Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71:1565–75.PubMed
49.
Abdel Salam OM. Fluoxetine and sertraline stimulate gastric acid secretion via a vagal pathway in anaesthetised rats. Pharmacol Res. 2004;50:309–16.PubMed
50.
de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106–9.PubMedPubMedCentral
51.
Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Int Med. 2003;163:59–64.
52.
Anglin R, Yuan YH, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:811–9.PubMed
53.
Guo C-G, Cheung KS, Zhang F, Chan EW, Chen L, Wong ICK, et al. Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis. Aliment Pharmacol Ther. 2019;50:1001–8.PubMed
54.
Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420–9.PubMed
55.
Crowe SE. Helicobacter pylori infection. NEJM. 2019;380:1158–65.PubMed
56.
Huang J-Q, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.PubMed
57.
Ng JC, Yeomans ND. Helicobacter pylori infection and the risk of upper gastrointestinal bleeding in low dose aspirin users: systematic review and meta-analysis. Med J Austr. 2018;209:306–11.
58.
Krag M, Perner A, Wetterslev J, et al. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med. 2015;41:833–45.PubMed
59.
Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001;5:368–75.PubMedPubMedCentral
60.
Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38:316–21.PubMedPubMedCentral
61.
Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet. 2000;356:1318–21.PubMed
62.
Leontiadis GI, Molloy-Bland M, Moayyedi P, Howden CW. Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:331–45.PubMed
63.
64.
Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–96.PubMed
65.
Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241–9.PubMed
66.
Lee S-J, Shin D-H, Hwang H-J, Kim JY, Pak HN, Lee MH, et al. Bleeding risk and major adverse events in patients with previous ulcer on oral anticoagulation therapy. Am J Cardiol. 2012;110:373–7.PubMed
67.
Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21:795–804.PubMed
68.
Gisbert JP, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez-Muñoz E. Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database of Syst Rev. 2004;(2):Art. No.: CD004062. https://​doi.​org/​10.​1002/​14651858.​CD004062.​pub2.
69.
Moayyedi P, Feltbower R, Brown J, Mason S, Mason J, Nathan J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet. 2000;355:1665–9.PubMed
70.
71.
IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC Working Group Reports 8.
72.
Fock KM, Katelaris P, Sugano K, Ang TL, Hunt RH, Talley NJ, et al. Second Asian-Pacific Consensus Guidelines for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2009;24:1587–600.PubMed
73.
74.
75.
GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:42–54.
76.
Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomised controlled trial. Gastroenterology. 2005;129:1910–7.PubMed
77.
Mason J, Axon ATR, Forman D, Duffett S, Drummond M, Crocombe W, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomised controlled trial. Aliment Pharmacol Ther. 2002;16:559–68.PubMed
78.
Harvey RF, Lane JA, Nair P, Egger M, Harvey I, Donovan J, et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations - the Bristol helicobacter project. Aliment Pharmacol Ther. 2010;32:394–400.PubMed
79.
80.
Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144:528–35.PubMed
81.
Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21:1411–8.PubMed
82.
Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:iii-iv 1–164.
83.
Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–38.PubMed
84.
Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135:41–60.PubMed
85.
Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3:231–41.PubMedPubMedCentral
86.
87.
Causada-Calo N, Germini F, Yuan Y, Eikelboom JW, Moayyedi P. Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy. Cochrane Database of Syst Rev. 2019;(8):Art. No.: CD013415. https://​doi.​org/​10.​1002/​14651858.​CD013415.
88.
Causada-Calo N, Germini F, Yuan Y, Eikelboom JW, Moayyedi P. Clopidogrel-based antithrombotic therapy for cardiovascular prevention: a systematic review and meta-analysis of randomized controlled trials. Gastroenterology. 2019;156(supplement 1):S97.
89.
•• Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682–91 Largest RCT in gastroenterology evaluating a pharmacological intervention and the first to evaluate PPI in patients taking anticoagulation. This trial suggested that PPI therapy reduced the risk of peptic ulcer and peptic ulcer bleeding, but the event rate was too low for this to be cost-effective in all patients taking anticoagulation.PubMed
90.
Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 recpetor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41:693–705.PubMed
91.
92.
•• Wang Y, Ye Z, Ge L, et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. BMJ. 2020;368:l6744. https://​doi.​org/​10.​1136/​bmj.​l6744Comprehensive network meta-analysis of all treatment options to prevent stress ulcer bleeding in intensive care patients. Acid suppressive therapy was effective but probably not beneficial in low risk patients.
93.
94.
Vaezi M, Yang Y-X, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153:35–48.PubMed
95.
Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid suppressive drugs. JAMA. 2004;292:1955–60.PubMed
96.
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.PubMed
97.
Neal KR, Scott HM, Slack RCB, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ. 1996;312:414–5.PubMedPubMedCentral
98.
Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patient with first time myocardial infarction: a nationwide propensity score matched analysis. BMJ. 2011;342:d2690.PubMedPubMedCentral
99.
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–46.PubMedPubMedCentral
100.
Gomm W, von Holt K, Thome F, Broich K, Maier W, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–6.PubMed
101.
Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for helicobacter pylori: a population-based study. Gut. 2018;67:28–35.PubMed
102.
Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735.PubMedPubMedCentral
103.
104.
105.
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020;115:1707–15.
106.
Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nature Reviews of Gastroenterology & Hepatology. 2012;9:132–9.
107.
• Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682–91 This trial evaluated the safety of PPIs with over 53,000 patients years of follow-up. There was no evidence of harm of PPIs apart from risk of enteric infections and the data suggested that the various harms of PPI described in observational studies are likely to be overestimated.PubMed
108.
Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41:1162–74.PubMed
109.
Jankowski JA, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392:400–8.PubMedPubMedCentral
110.
• Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–44 The first randomized trial evaluating PPI and aspirin to prevent progression of Barrett’s esophagus to neoplasia. If this trial started today there would be objection to such high doses of PPI being used for an average of 9 years, but mortality was reduced in the twice daily PPI group. The GI bleeding rate was very low in this trial giving indirect evidence to the benefit of this approach.PubMed
111.
Garcia-Rayado G, Navarro M, Lanas A. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs. Expert Rev Clin Pharmacol. 2018;11:1031–43.PubMed
112.
Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325:619–23.PubMedPubMedCentral
113.
Rostom A, Muir K, Dubé C, Jolicoeur E, Boucher M, Joyce J, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5:818–28.PubMed
114.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med. 2005;352:1092–102.PubMed
115.
Solomon SD, McMurray JJ, Pfeff er MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med. 2005;352:1071–80.PubMed
116.
Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79.
117.
118.
Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344–50.PubMed
119.
Taha AS, McCloskey C, McSkimming P, McConnachie A. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:469–76.PubMed
120.
Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease. J Gen Intern Med. 2003;18:1039–52.PubMedPubMedCentral
121.
Fallone CA, Gisbert JP, Chiba N, van Zanten SV, Fischbach L, et al. The Toronto helicobacter pylori consensus in context reply. Gastroenterology. 2017;152:303–4.PubMed
122.
Granholm A, Zeng L, Dionne JC, et al. Predictors of gastrointestinal bleeding in adult ICU patients: a systematic review and meta-analysis. Intensive Care Med. 2019;45:1347–59.PubMed
123.
Bo M, Gibello M, Brunetti E, Boietti E, Sappa M, Falcone Y, et al. Prevalence and predictors of inappropriate prescribing according to the screening tool of older people’s prescriptions and screening tool to alert to right treatment version 2 criteria in older patients discharged from geriatric and internal medicine wards: a prospective observational multicenter study. Geriatr Gerontol Int. 2019;19:5–11.PubMed
Metadaten
Titel
Who Needs Gastroprotection in 2020?
verfasst von
Takeshi Kanno
Paul Moayyedi, BSc MB ChB PhD MPH FRCP FRCPC AGAF, FACG, CAGF
Publikationsdatum
11.11.2020
Verlag
Springer US
Erschienen in
Current Treatment Options in Gastroenterology / Ausgabe 4/2020
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-020-00316-9

Weitere Artikel der Ausgabe 4/2020

Current Treatment Options in Gastroenterology 4/2020 Zur Ausgabe

Hot Topics

Managing Gastrointestinal Complications in Patients With Systemic Sclerosis

Pancreas (C Forsmark, Section Editor)

Management of Pancreatic Cystic Lesions: Making Sense of All the Guidelines

Hot Topics

Complementary Health Approaches for Irritable Bowel Syndrome

Pancreas (C Forsmark, Section Editor)

Management of Severe Acute Pancreatitis

Gastroenterology for Geriatric Patients (S Katz and A Afzali, Section Editors)

Biologic Therapy in Elderly Patients with IBD: Current Trends and Special Management Considerations

Gastroenterology for Geriatric Patients (S Katz and A Afzali, Section Editors)

Incorporating Frailty in the Treatment Program of Elderly Patients with Gastrointestinal Disease

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise